Endoxifen - Atossa Therapeutics
Alternative Names: (Z)-endoxifenLatest Information Update: 07 May 2024
At a glance
- Originator Atossa Genetics
- Developer Atossa Therapeutics; Weill Cornell Medicine
- Class Antineoplastics; Methylamines; Phenyl ethers; Small molecules; Stilbenes
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer; Ductal carcinoma; HER2 negative breast cancer
- Clinical Phase Unknown Ovarian cancer
- Preclinical Triple negative breast cancer
- No development reported Gynaecomastia